4.2 Short-Term Tactical Decision Scenarios

4.2 Short-Term Tactical Decision Scenarios

Short-term tactical decisions typically involve operational horizons of less than twelve months, during which plant capacity, core technology, and capital commitments remain largely fixed. Strategic management accountants apply relevant cost analysis across three frequent commercial dilemmas:

1. Make-or-Buy (Outsourcing) Decisions: Determining whether a component or sub-assembly should be manufactured in-house or procured from an external specialist.
2. Special Pricing Orders: Evaluating whether to accept a non-routine, discounted customer order during periods of excess or idle manufacturing capacity.
3. Product Line or Segment Discontinuation: Deciding whether to drop an apparently unprofitable division, department, or product line.

---

1. Make-or-Buy (Outsourcing) Decisions

In a make-or-buy decision, the financial objective is to minimize total relevant costs over the operating cycle.

The Incremental Cost Rule

An internal manufacturing process should only be abandoned in favor of external procurement if the external purchase price is strictly lower than the avoidable in-house costs plus any opportunity benefits realized by repurposing factory space:

$$\text{Avoidable In-House Costs} = \text{Direct Materials} + \text{Direct Labour} + \text{Variable Overheads} + \text{Avoidable Fixed Overheads}$$ $$\text{Relevant Make Cost} = \text{Avoidable In-House Costs} + \text{Opportunity Cost of Freed Capacity}$$ $$\text{Relevant Buy Cost} = \text{External Supplier Purchase Price} + \text{Incremental Handling / Inspection Costs}$$

Unavoidable fixed costs (such as factory building insurance, central site security, and corporate administration) will persist regardless of whether the component is made or bought. Including unavoidable fixed costs in the "Make" column artificially inflates internal production cost and produces flawed outsourcing decisions.

Qualitative and Strategic Risks in Outsourcing

Financial savings can quickly evaporate if operational vulnerabilities emerge:

• Supplier Price Gouging: Once internal tooling is dismantled and technical skills are lost, the external supplier possesses switching-cost leverage and may sharply raise prices.
• Quality Degradation: Substandard supplier components can damage brand reputation and trigger warranty claims.
• Supply Chain Lead-Time Volatility: Geopolitical disruption, freight bottlenecks, or supplier insolvency can halt downstream assembly lines.
• Intellectual Property (IP) Theft: Sharing proprietary technical drawings with third-party suppliers risks reverse-engineering and competitive leakage.

---

2. Special Pricing Orders

Enterprises often receive inquiries from international buyers, private-label distributors, or government agencies seeking bulk discounts below prevailing retail list prices.

The Acceptance Rule Under Idle Capacity

When an enterprise possesses idle or unutilized production capacity that cannot be deployed for standard commercial sales, fixed factory costs are already committed and will be incurred in full. Consequently, a special order is financially advantageous whenever the special bid price exceeds incremental variable and direct project-specific costs:

$$\text{Minimum Acceptable Bid Price} = \text{Incremental Variable Cost per Unit} + \frac{\text{Specific Incremental Fixed Costs}}{\text{Special Order Units}} + \text{Opportunity Cost per Unit}$$ $$\text{Incremental Contribution} = \text{Special Order Revenue} - \text{Incremental Costs} > 0$$

Strategic and Commercial Caveats

Accepting special orders below full absorption cost carries substantial strategic risks:

• Market Cannibalization: If the discounted buyer resells the goods into the firm's primary geographical territory, regular full-price customers will migrate to the discounted channel.
• Customer Price Retaliation: Existing clients paying regular list prices may demand parity or cancel long-term contracts if discounted pricing becomes public.
• Precedent Setting: Customers may refuse to return to standard commercial pricing once baseline price expectations have been anchored downward.

---

3. Product Line or Segment Discontinuation: The Death Spiral

A pervasive error in management accounting occurs when executive teams examine full absorption income statements and eliminate product lines or business units that report net operating losses.

The Allocated Overhead Death Spiral

When an operating division is closed, its sales revenue and variable costs disappear, alongside any direct avoidable fixed costs (e.g., dedicated plant leases or localized advertising). However, unavoidable allocated common corporate overheads do not vanish. Instead, the accounting department reallocates these fixed overheads across the surviving product lines. This inflates the reported unit costs of the remaining products, making them appear uncompetitive or unprofitable, which tempts management to close another line, triggering an overhead allocation death spiral.

┌─────────────────────────────────────────────────────────────┐
│         The Overhead Allocation Death Spiral Mechanism       │
└─────────────────────────────────────────────────────────────┘
   Segment shows net loss due to arbitrary overhead allocation
                          │
                          ▼
            Management terminates the segment
                          │
                          ▼
  Unavoidable corporate overhead persists unchanged in total cash
                          │
                          ▼
    Overhead is reallocated across fewer surviving segments
                          │
                          ▼
   Surviving segments show degraded margins and appear loss-making
                          │
                          ▼
         Cycle repeats until entire enterprise collapses

The Segment Margin Rule

A product line or operating segment should only be dropped if its contribution margin is less than its avoidable fixed costs. In other words, a segment should be retained whenever it generates a positive Segment Margin ($SM > 0$):

$$\text{Segment Margin} = \text{Segment Contribution Margin} - \text{Direct Avoidable Fixed Costs}$$ $$\text{Net Financial Impact of Closure} = \text{Avoidable Fixed Costs Saved} - \text{Lost Segment Contribution} - \text{Complementary Spillover Contribution Lost}$$

---

Corporate Application: Pacific Health Instruments Ltd

Pacific Health Instruments Ltd manufactures three diagnostic medical product lines: CardioScan, NeuroCheck, and DermaView. The management team is reviewing the annual segment income statement prepared under conventional full absorption costing:

Traditional Segment Performance Statement

The Chief Executive Officer proposed immediately discontinuing DermaView to eliminate its $90,000 reported loss, forecasting that company-wide net profit would increase from $250,000 to $340,000.

The Strategic Management Accounting Evaluation

The strategic management accountant investigated the operational dependencies and revealed three critical findings:

1. Corporate Overhead Persistence: The $240,000 of apportioned corporate overhead represents executive salaries, IT licenses, and legal retainers. None of these expenses will decrease if DermaView is discontinued. If DermaView is dropped, this $240,000 will be reallocated to CardioScan ($138,460) and NeuroCheck ($101,540).
2. Direct Segment Contribution: DermaView generates $420,000 of contribution margin and incurs only $270,000 of avoidable fixed costs. It generates a positive segment margin of +$150,000 toward covering corporate overheads.
3. Complementary Product Interdependence: Commercial hospitals bundle their diagnostic procurement contracts. Marketing intelligence indicates that 20% of CardioScan customers purchase CardioScan specifically because Pacific Health offers a unified software ecosystem with DermaView. Discontinuing DermaView will trigger a 15% cancellation rate in CardioScan sales (15% × $1,200,000 = $180,000 in lost CardioScan contribution margin).

Net Enterprise Profit Impact of Closing DermaView

$$\text{Avoidable Fixed Costs Saved} = +\text{\textdollar}270,000$$ $$\text{Lost DermaView Contribution Margin} = -\text{\textdollar}420,000$$ $$\text{Lost CardioScan Complementary Contribution} = -\text{\textdollar}180,000$$ $$\text{Net Enterprise Impact} = \text{\textdollar}270,000 - \text{\textdollar}420,000 - \text{\textdollar}180,000 = -\text{\textdollar}330,000$$

Instead of increasing profit by $90,000, discontinuing DermaView would plunge total enterprise profit from $250,000 to a net loss of -$80,000 ($250,000 - $330,000). The board accepted the accountant's analysis and retained the product line.

---

Exam Traps to Avoid